Physician profile
Oscar Ortiz
NPI 1396719662
$176,195.42
in general payments reported to CMS, 2019-2025
54 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $13K · 2021: $19K · 2022: $18K · 2023: $28K · 2024: $48K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Travel and Lodging: $12K · Food and Beverage: $8,519 · Education: $64.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,575.00 |
| Travel and Lodging | $12,233.11 |
| Food and Beverage | $8,519.49 |
| Education | $64.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $116,266.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $30,557.91 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $16,987.11 | 2019-2024 | |
| Novo Nordisk INC | $2,424.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $995.65 | 2019-2024 | Unithroid |
| Corcept Therapeutics | $985.59 | 2020-2025 | Korlym |
| Dexcom, INC. | $903.61 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $864.52 | 2019-2024 | Octrode, Freestyle Libre 3 |
| Intuity Medical INC | $650.31 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Bayer Healthcare Pharmaceuticals INC. | $637.48 | 2022-2025 | |
| Medtronic, INC. | $627.88 | 2022-2024 | Minimed 780g, Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Mannkind Corporation | $466.69 | 2019-2024 | Afrezza |
| Janssen Pharmaceuticals, INC | $440.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.77 | 2019-2024 | Jardiance |
| Valeritas, INC. | $278.71 | 2019 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.